Last reviewed · How we verify
Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Phyliance | fytic acid | PDRadiopharma Inc |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- PDRadiopharma Inc · 1 drug in Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer:
- Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer treatment updates — RSS
- Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer treatment updates — Atom
- Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/lymphoscintigraphy-in-cervical-cancer-uterine-neoplasms-vulvar-cancer-and-head-and-neck-canccer. Accessed 2026-06-10.
Related
- Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing